ES2628369T3 - Compuestos tricíclicos para inhibir el canal CFTR - Google Patents

Compuestos tricíclicos para inhibir el canal CFTR Download PDF

Info

Publication number
ES2628369T3
ES2628369T3 ES13826625.9T ES13826625T ES2628369T3 ES 2628369 T3 ES2628369 T3 ES 2628369T3 ES 13826625 T ES13826625 T ES 13826625T ES 2628369 T3 ES2628369 T3 ES 2628369T3
Authority
ES
Spain
Prior art keywords
dimethyl
alkyl
dione
pyrimido
pyrrolo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13826625.9T
Other languages
English (en)
Spanish (es)
Inventor
Mahbub AHMED
Alexander ASHALL-KELLY
Louisa GUERITZ
Jeffrey Mckenna
Joseph Mckenna
Simon MUTTON
Rakesh PARMAR
Jon SHEPHERD
Paul Wright
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50030372&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2628369(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Application granted granted Critical
Publication of ES2628369T3 publication Critical patent/ES2628369T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ES13826625.9T 2012-12-19 2013-12-17 Compuestos tricíclicos para inhibir el canal CFTR Active ES2628369T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261739335P 2012-12-19 2012-12-19
US201261739335P 2012-12-19
US201361906141P 2013-11-19 2013-11-19
US201361906141P 2013-11-19
PCT/IB2013/061043 WO2014097148A1 (en) 2012-12-19 2013-12-17 Tricyclic compounds for inhibiting the cftr channel

Publications (1)

Publication Number Publication Date
ES2628369T3 true ES2628369T3 (es) 2017-08-02

Family

ID=50030372

Family Applications (1)

Application Number Title Priority Date Filing Date
ES13826625.9T Active ES2628369T3 (es) 2012-12-19 2013-12-17 Compuestos tricíclicos para inhibir el canal CFTR

Country Status (25)

Country Link
US (2) US20140171417A1 (https=)
EP (1) EP2935278B1 (https=)
JP (1) JP6284546B2 (https=)
KR (1) KR20150097660A (https=)
CN (1) CN105143230B (https=)
AP (1) AP2015008539A0 (https=)
AR (1) AR094122A1 (https=)
AU (1) AU2013365739A1 (https=)
BR (1) BR112015014292A2 (https=)
CA (1) CA2895660A1 (https=)
CL (1) CL2015001730A1 (https=)
CR (1) CR20150325A (https=)
CU (1) CU20150066A7 (https=)
EA (1) EA201591177A1 (https=)
ES (1) ES2628369T3 (https=)
HK (1) HK1209741A1 (https=)
IL (1) IL239389A0 (https=)
MX (1) MX2015007939A (https=)
PE (1) PE20151055A1 (https=)
PH (1) PH12015501386A1 (https=)
SG (1) SG11201504594QA (https=)
TN (1) TN2015000279A1 (https=)
TW (1) TW201429974A (https=)
UY (1) UY35211A (https=)
WO (1) WO2014097148A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9056867B2 (en) 2011-09-16 2015-06-16 Novartis Ag N-substituted heterocyclyl carboxamides
AU2013365827A1 (en) 2012-12-19 2015-07-09 Novartis Ag Tricyclic compounds as CFTR inhibitors
EA201591177A1 (ru) 2012-12-19 2015-11-30 Новартис Аг Трициклические соединения для ингибирования канала cftr
TWI686429B (zh) 2014-09-19 2020-03-01 美商摩曼帝夫特性材料公司 用於經控制之矽氧烷交聯的鉑(ii)二烯錯合物
HUE054399T2 (hu) * 2015-04-23 2021-09-28 Trevi Therapeutics Inc Vegyületek viszketéses állapotok kezelésére
CN106478558B (zh) * 2016-10-17 2019-03-29 天津雅奥科技发展有限公司 一种4-羟甲基-二氢-呋喃-2(3h)-酮的合成方法
US12319686B2 (en) 2019-01-17 2025-06-03 Hoffmann-La Roche Inc. Process for the preparation of tetrahydropyridopyrimidines
BR112021025048A2 (pt) * 2019-06-12 2022-02-01 Univ California Métodos de tratamento de diarreia por ácido biliar
EP4329815A1 (en) 2021-04-29 2024-03-06 Novartis AG Deubiquitinase-targeting chimeras and related methods
CN117654560B (zh) * 2023-12-01 2024-06-04 安徽泽升科技股份有限公司 一种通过氧化氨基连续化制备硝基化合物的方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1207161B1 (en) 1999-08-25 2006-01-18 Banyu Pharmaceutical Co., Ltd. Novel isoindole derivatives
JP2002255967A (ja) 2001-02-27 2002-09-11 Banyu Pharmaceut Co Ltd イソインドール誘導体を有効成分とする糖尿病の治療剤、糖尿病の慢性合併症の予防剤又は肥満の治療剤。
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
AU2007332754A1 (en) 2006-12-12 2008-06-19 Schering Corporation Aspartyl protease inhibitors
WO2009042270A2 (en) * 2007-07-05 2009-04-02 Trustees Of Boston University Reca inhibitors and their uses as microbial inhibitors or potentiators of antibiotic activity
CA2709784A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
EP2464354B1 (en) * 2009-08-10 2015-04-01 The Regents of The University of California Pyrimido-pyrrolo-quinoxalinedione inhibitors of cystic fibrosis transmembrane conductance regulator protein and uses therefor
WO2012166658A1 (en) * 2011-05-27 2012-12-06 The Regents Of The University Of California Pyrimido-pyrrolo-oxazine-dione compound inhibitors of the cystic fibrosis transmembrane conductance regulator protein and uses therefor
AU2013365827A1 (en) 2012-12-19 2015-07-09 Novartis Ag Tricyclic compounds as CFTR inhibitors
EA201591177A1 (ru) 2012-12-19 2015-11-30 Новартис Аг Трициклические соединения для ингибирования канала cftr

Also Published As

Publication number Publication date
CR20150325A (es) 2015-08-10
JP2016509579A (ja) 2016-03-31
WO2014097148A9 (en) 2015-02-19
CN105143230B (zh) 2017-06-09
MX2015007939A (es) 2016-03-11
CU20150066A7 (es) 2015-11-27
EA201591177A1 (ru) 2015-11-30
CN105143230A (zh) 2015-12-09
JP6284546B2 (ja) 2018-02-28
HK1209741A1 (en) 2016-04-08
US20150336986A1 (en) 2015-11-26
AU2013365739A1 (en) 2015-07-09
AP2015008539A0 (en) 2015-06-30
PE20151055A1 (es) 2015-08-05
TN2015000279A1 (en) 2016-10-03
EP2935278B1 (en) 2017-03-15
BR112015014292A2 (pt) 2017-07-11
PH12015501386A1 (en) 2015-09-02
US9359381B2 (en) 2016-06-07
SG11201504594QA (en) 2015-07-30
CL2015001730A1 (es) 2015-08-28
TW201429974A (zh) 2014-08-01
US20140171417A1 (en) 2014-06-19
WO2014097148A1 (en) 2014-06-26
UY35211A (es) 2014-07-31
KR20150097660A (ko) 2015-08-26
AR094122A1 (es) 2015-07-08
CA2895660A1 (en) 2014-06-26
EP2935278A1 (en) 2015-10-28
IL239389A0 (en) 2015-07-30

Similar Documents

Publication Publication Date Title
ES2628369T3 (es) Compuestos tricíclicos para inhibir el canal CFTR
JP6712344B2 (ja) Betタンパク質阻害剤としての三環式複素環
US12528828B2 (en) Substituted pyrido[4,3-d]pyrimidines as KRAS modulators
CN104884458B (zh) 作为蛋白质激酶抑制剂的稠合杂环化合物
JP6629847B2 (ja) 縮合五員環イミダゾール誘導体
JP2025536369A (ja) Kras g12d分解剤及びその製造方法並びに応用
JP6284545B2 (ja) Cftr阻害としての三環式化合物
EP4129996A1 (en) Novel aminopyrimidine egfr inhibitor
WO2016007736A1 (en) Imidazopyrazines as lsd1 inhibitors
CN119604506A (zh) 4-烷氧基吡咯并[2,1-f][1,2,4]三嗪以及其制备和用途
ES2892624T3 (es) Compuestos tricíclicos y composiciones como inhibidores de cinasas
CN115873000A (zh) 异喹啉酮类及喹唑啉酮类化合物及其组合物和用途
CN121843948A (zh) 化合物、组合物和方法
KR20260019509A (ko) Gpr68 조절 활성을 갖는 이환식 헤테로아릴아미드
WO2025212729A1 (en) Macrocyclic compounds and their use
CN103492390A (zh) 氟苯基双环杂芳基化合物